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Is it Really a Penicillin Allergy?
Evaluation and Diagnosis of Penicillin Allergy for Healthcare 
Professionals
Did You Know? 5 Facts About Penicillin Allergy  
(Type 1, Immunoglobulin E (IgE)-mediated)
1. Approximately 10% of all U.S. patients report having an allergic reaction to a penicillin class antibiotic in their past. 
2. However, many patients who report penicillin allergies do not have true IgE-mediated reactions. When evaluated, fewer than 
1% of the population are truly allergic to penicillins.1 
3. Approximately 80% of patients with IgE-mediated penicillin allergy lose their sensitivity after 10 years.1 
4. Broad-spectrum antibiotics are often used as an alternative to penicillins. The use of broad-spectrum antibiotics in patients 
labeled “penicillin-allergic” is associated with higher healthcare costs, increased risk for antibiotic resistance, and suboptimal 
antibiotic therapy.1 
5. Correctly identifying those who are not actually penicillin-allergic can decrease unnecessary use of broad-spectrum antibiotics.1 
10% of the population reports a penicillin allergy but <1% of the whole 
population is truly allergic.
Before prescribing broad-spectrum antibiotics to a patient thought to be penicillin-allergic, evaluate the patient for  
true penicillin allergy (IgE-mediated) by conducting a history and physical, and, when appropriate, a skin test and 
challenge dose.
History and Physical Examination
The history and physical examination are important components  
when evaluating a patient’s drug reactions.1
 • Questions to ask during the examination:
 – What medication were you taking when the reaction occurred?
 – What kind of reaction occurred?
 – How long ago did the reaction occur?
 – How was the reaction managed? 
 – What was the outcome?2
 • Characteristics of an IgE-mediated (Type 1) reaction: 
 – Reactions that occur immediately or usually within one hour1
 – Hives: Multiple pink/red raised areas of skin that are intensely itchy3
 – Angioedema: Localized edema without hives affecting the abdomen, face, 
 extremities, genitalia, oropharynx, or larynx4
 – Wheezing and shortness of breath
 – Anaphylaxis1 requires signs or symptoms in at least two of the following systems:
  Skin: Hives, flushing, itching, and/or angioedema (continued on next page)
 • Broad-spectrum antibiotics are 
often used as an alternative to 
narrow-spectrum penicillins. 
 • Using broad-spectrum antibiotics 
can increase healthcare costs and 
antibiotic resistance, and may 
mean your patient receives less 
than the best care.
 • Correctly identifying if your patient 
is actually penicillin-allergic can 
decrease these risks by reducing 
unnecessary use of broad-
spectrum antibiotics.
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  Respiratory: Cough, nasal congestion, shortness of breath, chest tightness, wheeze, sensation of throat closure or choking, 
and/or change in voice-quality (laryngeal edema)
  Cardiovascular: Hypotension, faintness, tachycardia or less commonly bradycardia, tunnel vision, chest pain, sense of 
impending doom, and/or loss of consciousness
  Gastrointestinal: Nausea, vomiting, abdominal cramping, and diarrhea5
Penicillin Skin Tests and Challenge Doses
Based on the patient history and physical exam, additional tests may be needed to confirm a penicillin allergy. Penicillin 
skin testing is a reliable and useful method for evaluating IgE-mediated penicillin allergy.5 
A positive result means the patient is likely to have a penicillin allergy. If negative, the skin test is usually followed by an oral 
penicillin class challenge (e.g., with amoxicillin) to safely rule out an IgE-mediated penicillin allergy.1,7 
 • Skin tests currently include penicilloylpolylysine, the major antigenic determinant that indicates hypersensitivity  
to penicillin.
 • However, it is important to note that the patient can also be allergic to other reactive breakdown products, called minor 
determinants, which include penicillin G (benzylpenicillin), penicilloate, and penilloate—many of which are not commercially 
available. Of these, only penicillin G is available from pharmacies. 
 • To rule out penicillin allergy, an oral challenge dose can be done after skin testing. The negative predictive value of skin testing 
with the major and minor determinants is more than 95%, but approaches 100% when followed by a challenge dose.2
Special Considerations
Patients with severe hypersensitivity syndromes
Patients with other severe hypersensitivity syndromes—like Stevens-Johnson syndrome, toxic epidermal necrolysis, serum 
sickness, acute interstitial nephritis, hemolytic anemia, and drug rash with eosinophilia and systemic symptoms (DRESS)—should 
not use the offending drug in the future. The skin test and challenge described here are not appropriate for patients with these 
severe hypersensitivity syndromes.1,2,6  
Cephalosporin use in penicillin-allergic patients
Many cephalosporins, especially in the later generations, can be safely tolerated despite a penicillin allergy.6,8  Patients with 
anaphylaxis or other severe reactions to penicillin may require further evaluation prior to the use of cephalosporins.
Pediatric patients 
Children who are receiving amoxicillin or ampicillin and have Epstein-Barr virus infection can develop a non-allergic, non-pruritic 
rash that can appear similar to an IgE-mediated reaction.1,9 
For more information about appropriate antibiotic use, visit www.cdc.gov/getsmart.
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